Cited by 290Cancer Genomics and DiagnosticsCancer Cells and MetastasisAcute Lymphoblastic Leukemia research

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Orthotopic patient-derived xenografts of paediatric solid tumours

Open access

Stewart, Elizabeth, Federico, Sara M., Chen, Xiang, Shelat, Anang A., Bradley, Cori, Gordon, Brittney, Karlstrom, Asa, Twarog, Nathaniel R., Clay, Michael R., Bahrami, Armita, Freeman, Burgess B., Xu, Beisi, Zhou, Xin, Wu, Jianrong, Honnell, Victoria, Ocarz, Monica, Blankenship, Kaley, Dapper, Jason, Mardis, Elaine R., Wilson, Richard K., Downing, James, Zhang, Jinghui, Easton, John, Pappo, Alberto, Dyer, Michael A.·2017·Nature

DOI 10.1038/nature23647PMC PMC5659286

Open this paper in CoChat — free account

Abstract

Paediatric solid tumours arise from endodermal, ectodermal, or mesodermal lineages. Although the overall survival of children with solid tumours is 75%, that of children with recurrent disease is below 30%. To capture the complexity and diversity of paediatric solid tumours and establish new models of recurrent disease, here we develop a protocol to produce orthotopic patient-derived xenografts at diagnosis, recurrence, and autopsy. Tumour specimens were received from 168 patients, and 67 orthotopic patient-derived xenografts were established for 12 types of cancer. The origins of the patient-derived xenograft tumours were reflected in their gene-expression profiles and epigenomes. Genomic profiling of the tumours, including detailed clonal analysis, was performed to determine whether the clonal population in the xenograft recapitulated the patient's tumour. We identified several drug vulnerabilities and showed that the combination of a WEE1 inhibitor (AZD1775), irinotecan, and vincristine can lead to complete response in multiple rhabdomyosarcoma orthotopic patient-derived xenografts tumours in vivo.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature23647

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
ChromHMM: automating chromatin-state discovery and characterization
Ernst, J., & Kellis, M. (2012) · Nature Methods · doi:10.1038/nmeth.1906 · Cited by 2,482
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Bioassay Analysis using R
Ritz, C., & Streibig, J. C. (2005) · Journal of Statistical Software · doi:10.18637/jss.v012.i05 · Cited by 1,456
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations
Campbell, I. (2007) · Statistics in Medicine · doi:10.1002/sim.2832 · Cited by 912
Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Self-citation
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681

Show all 30 references

Sorted by citations

Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
Rhabdomyosarcoma
Skapek, S. X., Ferrari, A., Gupta, A. A., Lupo, P. J., Butler, E. B., SHIPLEY, J. M., Barr, F. G., & Hawkins, D. S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0051-2 · Cited by 909
Ewing sarcoma
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
Slyper, M., Porter, C. B. M., Ashenberg, O., Waldman, J., Drokhlyansky, E., Wakiro, I., Smillie, C. S., Smith-Rosario, G., Wu, J., Dionne, D. A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0844-1 · Cited by 758
Self-citation
Osteosarcoma
Beird, H. C., Bielack, S. S., Flanagan, A. M., Gill, J., Heymann, D., Janeway, K. A., Livingston, J. A., Roberts, R. D., Strauss, S. J., & Gorlick, R. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00409-y · Cited by 660
Genome-Informed Targeted Therapy for Osteosarcoma
Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1152 · Cited by 452
Sarcoma treatment in the era of molecular medicine
Grünewald, T. G., Alonso, M., Avnet, S., Banito, A., Burdach, S., Cidre‐Aranaz, F., Di Pompo, G., Distel, M., Dorado‐Garcia, H., Garcia‐Castro, J., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911131 · Cited by 319
The Circular RNA circPRKCI Promotes Tumor Growth in Lung Adenocarcinoma
Qiu, M., Xia, W., Chen, R., Wang, S., Xu, Y., Ma, Z., Xu, W., Zhang, E., Wang, J., Tian, F., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2808 · Cited by 287
St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem
McLeod, C., Gout, A. M., Zhou, X., Thrasher, A., Rahbarinia, D., Brady, S. W., Macias, M., Birch, K., Finkelstein, D., Sunny, J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1230 · Cited by 274
Self-citation
Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish
Yan, C., Brunson, D. C., Tang, Q., Do, D., Iftimia, N. A., Moore, J. C., Hayes, M. N., Welker, A. M., Garcia, E. G., Dubash, T. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.004 · Cited by 242
Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma
Vaubel, R. A., Tian, S., Remonde, D., Schroeder, M. A., Mladek, A. C., Kitange, G. J., Caron, A., Kollmeyer, T. M., Grove, R., Peng, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0909 · Cited by 227
Genomic evolution of cancer models: perils and opportunities
Ben‐David, U., Beroukhim, R., & Golub, T. R. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0095-3 · Cited by 234
Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
Rokita, J. L., Rathi, K. S., Cardenas, M., Upton, K. A., Jayaseelan, J. C., Cross, K. L., Pfeil, J., Egolf, L. E., Way, G. P., Farrel, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.071 · Cited by 185
A biobank of patient-derived pediatric brain tumor models
Brabetz, S., Leary, S. E. S., Gröbner, S. N., Nakamoto, M. W., Seker‐Cin, H., Girard, E. J., Cole, B., Strand, A. D., Bloom, K., Hovestadt, V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0207-3 · Cited by 178
XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data
Kluin, R. J. C., Kemper, K., Kuilman, T., de Ruiter, J. R., Iyer, V., Forment, J. V., Cornelissen‐Steijger, P., de Rink, I., ter Brugge, P., Song, J., et al. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2353-5 · Cited by 167
Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours
Jones, D., Banito, A., Grünewald, T. G. P., Haber, M., Jäger, N., Kool, M., Milde, T., Molenaar, J. J., Nabbi, A., Pugh, T. J., et al. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0169-x · Cited by 161
Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses
Stewart, E., McEvoy, J., Wang, H., Chen, X., Honnell, V., Ocarz, M., Gordon, B., Dapper, J., Blankenship, K., Yang, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.012 · Cited by 153
Self-citation
Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids
Mao, Y., Wang, W., Yang, J., Zhou, X., Lu, Y., Gao, J., Wang, X., Wen, L., Fu, W., & Tang, F. (2023) · Protein & Cell · doi:10.1093/procel/pwad038 · Cited by 155
Self-citation
Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis
Bukhari, A. B., Lewis, C. W., Pearce, J. J., Luong, D., Chan, G. K. T., & Gamper, A. M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122622 · Cited by 141
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
Zeineldin, M., Federico, S. M., Chen, X. '., Fan, Y., Xu, B., Stewart, E. A., Zhou, X., Jeon, J., Griffiths, L. M., Nguyen, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14682-6 · Cited by 128
Self-citation
Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models
Huang, Y., Huang, Z., Tang, Z., Chen, Y., Huang, M., Liu, H., Huang, W., Ye, Q., & Jia, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.740574 · Cited by 134
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group
Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen‐Rhoades, W., Fan, T., Khanna, C., Sweet‐Cordero, E. A., Cash, T., et al. (2019) · Cancer · doi:10.1002/cncr.32351 · Cited by 127
Molecular mechanisms underpinning sarcomas and implications for current and future therapy
Damerell, V., Pepper, M. S., & Prince, S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00647-8 · Cited by 120
Retinoblastoma from human stem cell-derived retinal organoids
Norrie, J. L., Nityanandam, A., Lai, K., Chen, X. '., Wilson, M. W., Stewart, E. A., Griffiths, L. M., Jin, H., Wu, G., Orr, B. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24781-7 · Cited by 110
Self-citation
Patient-derived tumor-like cell clusters for drug testing in cancer therapy
Yin, S., Xi, R., Wu, A., Wang, S., Li, Y., Wang, C., Tang, L., Xia, Y., Yang, D., Li, J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz1723 · Cited by 104
Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery
Dhaliwal, A. K., & Zheng, G. (2019) · Theranostics · doi:10.7150/thno.37204 · Cited by 107
Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment
Zhu, Y.-H., Zheng, J.-H., Jia, Q.-Y., Duan, Z., Yao, H., Yang, J., Sun, Y., Jiang, S.-H., Liu, D., & Huo, Y. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00741-1 · Cited by 98
Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field
Williams, J. A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7030041 · Cited by 97
Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression
Fan, T. M., Roberts, R. D., & Lizardo, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00013 · Cited by 90
Chimeric protein probes for C5a receptors through fusion of the anaphylatoxin C5a core region with a small-molecule antagonist
Zuo, C., Shi, W., Chen, X., Glatz, M., Riedl, B., Flamme, I., Pook, E., Wang, J., Fang, G., Bierer, D. E., et al. (2019) · Science China Chemistry · doi:10.1007/s11426-019-9513-2 · Cited by 83
Self-citation
Sarcoma Spheroids and Organoids—Promising Tools in the Era of Personalized Medicine
Colella, G., Fazioli, F., Gallo, M., Chiara, A. D., Apice, G., Ruosi, C., Cimmino, A., & de Nigris, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020615 · Cited by 88
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
Nanni, P., Landuzzi, L., Manara, M. C., Righi, A., Nicoletti, G., Cristalli, C., Pasello, M., Parra, A., Carrabotta, M., Ferracin, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48634-y · Cited by 82
The clonal evolution of metastatic colorectal cancer
Dang, H. X., Krasnick, B. A., White, B. S., Grossman, J. G., Strand, M. S., Zhang, J., Cabanski, C. R., Miller, C. A., Fulton, R. S., Goedegebuure, S. P., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9691 · Cited by 83
Self-citation
Canine and murine models of osteosarcoma
Beck, J. A., Ren, L., Huang, S., Berger, E. P., Bardales, K., Mannheimer, J., Mazcko, C. N., & LeBlanc, A. K. (2022) · Veterinary Pathology · doi:10.1177/03009858221083038 · Cited by 84
The secret lives of cancer cell lines
Hynds, R. E., Vladimirou, E., & Janes, S. M. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.037366 · Cited by 81
Insights into pediatric rhabdomyosarcoma research: Challenges and goals
Yohe, M. E., Heske, C. M., Stewart, E. A., Adamson, P. C., Ahmed, N. M., Antonescu, C. R., Chen, E. Y., Collins, N. B., Ehrlich, A. R., Galindo, R. L., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27869 · Cited by 77
Self-citation
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe
Hettmer, S., Linardic, C. M., Kelsey, A. M., Rudzinski, E. R., Vokuhl, C., Selfe, J., Ruhen, O., Shern, J. F., Khan, J. I., Kovach, A. R., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.05.036 · Cited by 80
Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
Tang, M., Svirskis, D. M., Leung, E. Y., Kanamala, M., Wang, H., & Wu, Z. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.018 · Cited by 75
Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies
Vakili‐Samiani, S., Jalil, A. T., Abdelbasset, W. K., Yumashev, A. V., Karpisheh, V., Jalali, P., Adibfar, S., Ahmadi, M., Feizi, A. A. H., & Jadidi‐Niaragh, F. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103203 · Cited by 74
The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma
Patel, A. G., Chen, X. '., Huang, X., Clay, M. R., Komarova, N. L., Krasin, M. J., Pappo, A. S., Tillman, H. S., Orr, B. A., McEvoy, J. D., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.04.003 · Cited by 79
Self-citation
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy
Fu, S., Wang, Y., Keyomarsi, K., & Meric-Bernstein, F. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1511700 · Cited by 71
Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers
Wolpaw, A. J., Bayliss, R. W., Büchel, G., Dang, C. V., Eilers, M., Gustafson, W. C., Hansen, G. M., Jura, N., Knapp, S., Lemmon, M. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3108 · Cited by 74
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM
Peterziel, H., Jamaladdin, N., ElHarouni, D., Gerloff, X. F., Herter, S., Fiesel, P., Berker, Y., Blattner-Johnson, M., Schramm, K., Jones, B. C., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00335-y · Cited by 69
The design, analysis and application of mouse clinical trials in oncology drug development
Guo, S., Jiang, X., Mao, B., & Li, Q.-X. (2019) · BMC Cancer · doi:10.1186/s12885-019-5907-7 · Cited by 68
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma
Wei, Y., Qin, Q., Yan, C., Hayes, M. N., Garcia, S. P., Xi, H., Do, D., Jin, A., Eng, T. C. Y., McCarthy, K. M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00414-w · Cited by 72
Hit Triage and Validation in Phenotypic Screening: Considerations and Strategies
Vincent, F., Loria, P. M., Weston, A. D., Steppan, C. M., Doyonnas, R., Wang, Y., Rockwell, K. L., & Peakman, M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.08.009 · Cited by 60
The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development
Langenberg, K. P. S., Looze, E. J., & Molenaar, J. J. (2021) · Cancers · doi:10.3390/cancers13174324 · Cited by 61
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity
Zucchini, C., Manara, M. C., Cristalli, C., Carrabotta, M., Greco, S., Pinca, R. S., Ferrari, C., Landuzzi, L., Pasello, M., Lollini, P., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1506-3 · Cited by 58
Recent advances in microfluidic technology and applications for anti-cancer drug screening
Shi, Y., Cai, Y., Cao, Y., Hong, Z., & Chai, Y. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.116118 · Cited by 60
Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes
Meister, M. T., Koerkamp, M. J. A. G., de Souza, T. M., Breunis, W. B., Frazer‐Mendelewska, E., Brok, M. O., DeMartino, J., Manders, F., Calandrini, C., Kerstens, H. H. D., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216001 · Cited by 57
High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer
Mayoh, C., Mao, J., Xie, J., Tax, G., Chow, S., Cadiz, R., Pazaky, K., Barahona, P., Ajuyah, P., Trebilcock, P., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3702 · Cited by 56
Animal Models in Microbeam Radiation Therapy: A Scoping Review
Fernández-Palomo, C., Fazzari, J., Trappetti, V., Smyth, L. M. L., Janka, H., Laissue, J. A., & Djonov, V. (2020) · Cancers · doi:10.3390/cancers12030527 · Cited by 53
An overview of neuroblastoma cell lineage phenotypes and in vitro models
Cogo, S. C., do Nascimento, T. G. F. D. C., Pinhatti, F. D. A. B., de França, N., Rodrigues, B. S., Cavalli, L. R., & Elífio-Esposito, S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220949237 · Cited by 50
Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy
Kamili, A., Gifford, A. J., Li, N., Mayoh, C., Chow, S., Failes, T. W., Eden, G. L., Cadiz, R., Xie, J., Lukeis, R. E., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0682-4 · Cited by 50
Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma
Danielli, S. G., Wei, Y., Dyer, M. A., Stewart, E. A., Sheppard, H., Wachtel, M., Schäfer, B. W., Patel, A. G., & Langenau, D. M. (2024) · Nature Communications · doi:10.1038/s41467-024-50527-2 · Cited by 49
Self-citation
Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage
Zerbib, J., Ippolito, M. R., Eliezer, Y., Feudis, G. D., Reuveni, E., Kadmon, A. S., Martin, S., Viganò, S., Leor, G., Berstler, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52176-x · Cited by 49
An evolutionary framework for treating pediatric sarcomas
Reed, D. R., Metts, J. L., Pressley, M., Fridley, B. L., Hayashi, M., Isakoff, M. S., Loeb, D. M., Makanji, R. J., Roberts, R. D., Trucco, M. M., et al. (2020) · Cancer · doi:10.1002/cncr.32777 · Cited by 48
Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach
Schott, C. R., Koehne, A. L., Sayles, L. C., Young, E. P., Luck, C., Yu, K., Lee, A. G., Breese, M. R., Leung, S. G., Xu, H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0873 · Cited by 47
Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity
Manzella, G., Schreck, L. D., Breunis, W. B., Molenaar, J. J., Merks, J. H. M., Barr, F. G., Sun, W., Römmele, M., Zhang, L., Tchinda, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18388-7 · Cited by 46
Clinical, Genomic, and Pharmacological Study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma
Zugbi, S., Ganiewich, D., Bhattacharyya, A., Aschero, R., Ottaviani, D., Sampor, C., Cafferata, E. G. A., Mena, M. D., Sgroi, M., Winter, U., et al. (2020) · Cancers · doi:10.3390/cancers12092714 · Cited by 45
CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice
Li, N., Torres, M. B., Spetz, M. R., Wang, R., Peng, L., Tian, M., Dower, C. M., Nguyen, R., Sun, M., Tai, C., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100297 · Cited by 47
Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts
Sturtzel, C., Grissenberger, S., Bozatzi, P., Scheuringer, E., Wenninger-Weinzierl, A., Zajec, Ž., Dernovšek, J., Pascoal, S., Gehl, V., Kutsch, A., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00386-9 · Cited by 44
The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo
Xu, N., Hua, Z., Ba, G., Zhang, S., Liu, Z., Thiele, C. J., & Li, Z. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1107-1 · Cited by 44
Targeted Therapy–based Combination Treatment in Rhabdomyosarcoma
van Erp, A. E. M., Versleijen‐Jonkers, Y. M. H., van der Graaf, W. T. A., & Fleuren, E. D. G. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1131 · Cited by 43
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer
Lau, L. M. S., Mayoh, C., Xie, J., Barahona, P., MacKenzie, K. L., Wong, M., Kamili, A., Tsoli, M., Failes, T. W., Kumar, A., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114608 · Cited by 45
The myokine Fibcd1 is an endogenous determinant of myofiber size and mitigates cancer-induced myofiber atrophy
Graça, F. A., Rai, M., Hunt, L. C., Stephan, A., Wang, Y., Gordon, B., Wang, R., Quarato, G., Xu, B., Fan, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30120-1 · Cited by 41
Self-citation
Increased RNA and Protein Degradation Is Required for Counteracting Transcriptional Burden and Proteotoxic Stress in Human Aneuploid Cells
Ippolito, M. R., Zerbib, J., Eliezer, Y., Reuveni, E., Viganò, S., Feudis, G. D., Shulman, E. D., Kadmon, A. S., Slutsky, R., Chang, T., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0309 · Cited by 43
Longitudinal high-resolution imaging through a flexible intravital imaging window
Jacquemin, G., Benavente-Diaz, M., Djaber, S., Bore, A., Dangles‐Marie, V., Surdez, D., Tajbakhsh, S., Fré, S., & Lloyd‐Lewis, B. (2021) · Science Advances · doi:10.1126/sciadv.abg7663 · Cited by 40
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
Landuzzi, L., Manara, M. C., Lollini, P.-L., & Scotlandi, K. (2021) · Cells · doi:10.3390/cells10020416 · Cited by 39
Cir-ITCH inhibits gastric cancer migration, invasion and proliferation by regulating the Wnt/β-catenin pathway
Yang, P., & Wang, H. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-74452-8 · Cited by 39
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
Odeniyide, P., Yohe, M. E., Pollard, K., Vaseva, A. V., Calizo, A., Zhang, L., Rodríguez, F. J., Gross, J. M., Allen, A. N., Wan, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02305-x · Cited by 38
HNRNPH1 is required for rhabdomyosarcoma cell growth and survival
Li, Y., Bakke, J., Finkelstein, D., Zeng, H., Wu, J., & Chen, T. (2018) · Oncogenesis · doi:10.1038/s41389-017-0024-4 · Cited by 38
Self-citation
Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma
McGuire, J., Nerlakanti, N., Lo, C. H., Tauro, M., Utset‐Ward, T. J., Reed, D. R., & Lynch, C. C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33046 · Cited by 40
Simple droplet microfluidics platform for drug screening on cancer spheroids
Parent, C., Kiran Raj, M., Zhou, Y., Aubert, V., Surdez, D., Delattre, O., Wilhelm, C., & Viovy, J. (2023) · Lab on a Chip · doi:10.1039/d3lc00417a · Cited by 37
Predicting Cancer Drug Response In Vivo by Learning an Optimal Feature Selection of Tumour Molecular Profiles
Nguyen, L. C., Naulaerts, S., Bomane, A., Bruna, A., Ghislat, G., & Ballester, P. J. (2021) · Biomedicines · doi:10.3390/biomedicines9101319 · Cited by 36
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors
Costa, M. E. M. D., Zaïdi, S., Scoazec, J., Droit, R., Lim, W. C., Marchais, A., Salmon, J., Cherkaoui, S., Morscher, R. J., Laurent, A. P., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05320-0 · Cited by 35
Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity
Alptekin, A., Ye, B., Yu, Y., Poole, C. J., van Riggelen, J., Zha, Y., & Ding, H. (2019) · Oncogene · doi:10.1038/s41388-019-0967-3 · Cited by 35
Immune characterization of pre-clinical murine models of neuroblastoma
Webb, E. R., Lanati, S., Wareham, C., Easton, A., Dunn, S. N., Inzhelevskaya, T., Sadler, F. M., James, S., Ashton‐Key, M., Cragg, M. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73695-9 · Cited by 36
Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma
Yu, Y., Ding, J., Zhu, S., Alptekin, A., Dong, Z., Yan, C., Zha, Y., & Ding, H. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04120-w · Cited by 35
A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneityPreprint
Patel, A. G., Ashenberg, O., Collins, N. B., Segerstolpe, Å., Jiang, S., Slyper, M., Huang, X., Caraccio, C., Jin, H., Sheppard, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.07.574538 · Cited by 39
Self-citation
Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR
Lam, P. Y., Omer, N., Wong, J., Tu, C., Alim, L., Rossi, G. R., Victorova, M., Tompkins, H., Lin, C., Mehdi, A. M., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70140 · Cited by 35
Positron Emission Tomography Detects In Vivo Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma
Butch, E. R., Mead, P. E., Diaz, V. A., Sheppard, H., Stewart, E. A., Mishra, J. K., Kim, J.-E., Bahrami, A., Dearling, J. L. J., Packard, A. B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3340 · Cited by 34
Self-citation
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Tucker, E. R., Jiménez, I., Chen, L., Bellini, A., Gorrini, C., Calton, E. A., Gao, Q., Che, H., Poon, E., Jamin, Y., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2274 · Cited by 35
Barriers to accessing public cancer genomic data
Learned, K., Durbin, A., Currie, R., Kephart, E. T., Beale, H. C., Sanders, L. M., Pfeil, J., Goldstein, T. C., Salama, S. R., Haussler, D., et al. (2019) · Scientific Data · doi:10.1038/s41597-019-0096-4 · Cited by 34
Recent Advances in Pediatric Cancer Research
McEachron, T. A., & Helman, L. J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1191 · Cited by 35
Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma
Hansson, K., Radke, K., Aaltonen, K. E., Saarela, J., Mañas, A., Sjölund, J., Smith, E. M. K., Pietras, K., Påhlman, S., Wennerberg, K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4434 · Cited by 33
Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models
Gatzweiler, C., Ridinger, J., Herter, S., Gerloff, X. F., ElHarouni, D., Berker, Y., Imle, R., Schmitt, L., Kreth, S., Stainczyk, S. A., et al. (2022) · Cancers · doi:10.3390/cancers14030849 · Cited by 33
Patient-derived xenograft models in musculoskeletal malignancies
Wan, L., Chao, T., Chen, R., Su, J., & Li, Z. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1487-6 · Cited by 32
Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression
Shaw, T. I., Wagner, J., Tian, L., Wickman, E., Poudel, S., Wang, J., Paul, R., Koo, S. C., Lu, M., Sheppard, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47649-y · Cited by 31
Self-citation
Patient-derived xenograft models in hepatopancreatobiliary cancer
Pan, B., Wei, X., & Xu, X. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02454-9 · Cited by 31
Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time
Rajan, S., Zaccaria, S., Cannon, M. V., Cam, M., Gross, A. C., Raphael, B. J., & Roberts, R. D. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0348 · Cited by 32
Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses
Contreras-Trujillo, H., Eerdeng, J., Akre, S., Du, J., Contreras, J., Gala, B., Vergel-Rodriguez, M., Lee, Y., Jorapur, A., Andreasian, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26771-1 · Cited by 30
Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies
Schott, C. R., Shah, A. T., & Sweet-Cordero, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43085-6_1 · Cited by 30
An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs
Chapple, R. H., Liu, X., Natarajan, S., Alexander, M. I. M., Kim, Y., Patel, A. G., LaFlamme, C. W., Pan, M., Wright, W. C., Lee, H.-M., et al. (2024) · Genome biology · doi:10.1186/s13059-024-03309-4 · Cited by 31
Self-citation
Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research
Wang, W., Li, Y., Lin, K., Wang, X., Tu, Y., & Zhuo, Z. (2023) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12349 · Cited by 29
IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors
Wickman, E., Lange, S., Wagner, J., Ibañez-Vega, J., Tian, L., Lu, M., Sheppard, H., Chiang, J., Koo, S. C., Vogel, P., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009743 · Cited by 27
Self-citation
Establishment and evaluation of four different types of patient-derived xenograft models
Ji, X., Chen, S., Guo, Y., Li, W., Qi, X., Yang, H., Xiao, S., Fang, G., Hu, J., Wen, C., et al. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0497-4 · Cited by 27
The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors
Goss, K. L., Koppenhafer, S. L., Waters, T. W., Terry, W. W., Wen, K., Wu, M., Ostergaard, J., Gordon, P. M., & Gordon, D. J. (2020) · Oncogene · doi:10.1038/s41388-020-01552-0 · Cited by 28
Prognostic value of patient‐derived xenograft engraftment in pediatric sarcomas
Castillo‐Ecija, H., Pascual‐Pasto, G., Pérez‐Jaume, S., Resa‐Pares, C., Vilà-Ubach, M., Monterrubio, C., Jimenez‐Cabaco, A., Baulenas‐Farres, M., Muñoz‐Aznar, O., Salvador, N., et al. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.210 · Cited by 27
Cancer metastasis chemoprevention prevents circulating tumour cells from germination
Xie, X., Li, Y., Lian, S., Lu, Y., & Jia, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01174-w · Cited by 27

Authors: Stewart, E., Federico, S. M., Chen, X., Shelat, A. A., Bradley, C., Gordon, B., Karlstrom, A., Twarog, N. R., Clay, M. R., Bahrami, A., Freeman, B. B., Xu, B., Zhou, X., Wu, J., Honnell, V., Ocarz, M., Blankenship, K., Dapper, J., Mardis, E. R., Wilson, R. K., Downing, J., Zhang, J., Easton, J., Pappo, A., & Dyer, M. A.
Affiliations: St. Jude Children's Research Hospital (US)
Washington University in St. Louis (US)
Corresponding author: Dyer, Michael A.
ORCID: Stewart, Elizabeth
Federico, Sara M.
Chen, Xiang
Shelat, Anang A.
Twarog, Nathaniel R.
Clay, Michael R.
Bahrami, Armita
Freeman, Burgess B.
Xu, Beisi
Zhou, Xin
Wu, Jianrong
Honnell, Victoria
Mardis, Elaine R.
Wilson, Richard K.
Downing, James
Zhang, Jinghui
Easton, John
Pappo, Alberto
Dyer, Michael A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2017-08-30
Volume: 549
Issue: 7670
Pages: 96-100
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature23647
PMC: PMC5659286
OpenAlex: W2750663875
Cited by: 286
References: 30
Citations by year: 2026: 19 · 2025: 20 · 2024: 31 · 2023: 32 · 2022: 33 · 2021: 47 · 2020: 46 · 2019: 31 · 2018: 24 · 2017: 3
FWCI: 9.31
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Howard Hughes Medical Institute
National Eye Institute (R01EY014867, R01EY018599)
National Cancer Institute (R01CA219686, R01CA168875, P30CA021765)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords: pediatric solid tumors, rhabdomyosarcoma, tumor recurrence, clonal analysis, drug screening, predictive biomarkers, WEE1 inhibitor, AZD1775, irinotecan, vincristine, combination therapy, cancer cell lines
MeSH terms: Bortezomib, Irinotecan, Panobinostat, Animals, Camptothecin, Child, Clone Cells, Drug Therapy, Combination, Female, Humans, Hydroxamic Acids, Indoles, Neoplasms, Nuclear Proteins, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Pyrimidinones, Rhabdomyosarcoma, Vincristine, Cell Cycle Proteins, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, High-Throughput Screening Assays, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Orthotopic patient-derived xenografts of paediatric solid tumours

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks